Towards Improved Respiratory Outcomes In Preterm Infants Through Rapid And Effective Aerosalisation Of Medication To The Lung
Funder
National Health and Medical Research Council
Funding Amount
$318,768.00
Summary
Babies born premature are greatest at risk from increasingly common respiratory illnesses. It is possible that delivering a medication by aerosol will be the most effective method of treatment. For premature babies that need breathing support, inhaled medication could improve care. For highly infectious respiratory illnesses such as RSV, with no vaccines available, we need to protect babies very early in life. I will use an established lamb model to test fast medication delivery to the lungs.
Comparing Pneumococcal Vaccines In A High Risk Population: A Randomised Controlled Trial Of Immunogenicity, Safety And Impact On Carriage Of Pneumococcal Conjugate And Polysaccharide Vaccines In Infants In Papua New Guinea
Funder
National Health and Medical Research Council
Funding Amount
$1,042,670.00
Summary
Pneumococcal disease is a major cause of pneumonia and meningitis in infants in developing countries in particular resulting in an estimated 800,000 deaths each year. This project will study how well pneumococcal vaccines perform in 260 high-risk infants in Papua New Guinea. We will examine how well the vaccines stimulate protective immunity and reduce babies carrying the pneumococcal bacteria in their nose and how long this immunity lasts for. The study will inform global immunisation policy.
Strategies To Reduce The Burden Of Gastroenteritis In Aboriginal Children.
Funder
National Health and Medical Research Council
Funding Amount
$124,676.00
Summary
Rotavirus is the leading cause of severe gastroenteritis in children. Despite early promise, vaccines which target rotavirus seem to be less effective in low-resource settings and also amongst Australian Indigenous children. This study seeks to assess whether an extra dose of rotavirus vaccine (RV1) will improve the effectiveness of rotavirus vaccine in Aboriginal children and result in decreased admissions and clinic visits in the first three years of life.
Otitis Media, Hearing Loss And School Readiness Of Indigenous Children Followed From Birth In Two Randomised Controlled Trials Of Novel Pneumococcal Conjugate Vaccine Schedules (VOICES. Vaccines To Prevent Otitis Media In Children Entering School)
Funder
National Health and Medical Research Council
Funding Amount
$1,317,169.00
Summary
Educational and health outcomes of Indigenous children are extremely poor, particularly in remote areas. High rates of ear disease, particularly “runny ears” and “glue ear”, and hearing loss throughout early childhood contribute to developmental delay. Vaccines to prevent ear disease could be used more effectively. This project is evaluating a novel combination schedule of two different licenced vaccine formulations to maximise protection and improve ear health, hearing and school readiness.
Transcriptional Regulation Of The Tumour Suppressor Gene, Retinoic Acid Receptor Beta
Funder
National Health and Medical Research Council
Funding Amount
$336,540.00
Summary
Cancer is still the second commonest cause of death in children. Neuroblastoma is the commonest solid tumour under the age of five years. Neuroblastoma responds poorly to conventional chemotherapy, unlike many other childhood cancers, and thus represents a major unsolved child health problem. A major advance in the field was a recent trial in th US demonstrating that treatment with oral vitamin A improved survival rates in children with advanced neuroblastoma. In previous studies we have identif ....Cancer is still the second commonest cause of death in children. Neuroblastoma is the commonest solid tumour under the age of five years. Neuroblastoma responds poorly to conventional chemotherapy, unlike many other childhood cancers, and thus represents a major unsolved child health problem. A major advance in the field was a recent trial in th US demonstrating that treatment with oral vitamin A improved survival rates in children with advanced neuroblastoma. In previous studies we have identified that a particular gene retinoic acid receptor beta, known to be involved in the vitamin A anticancer effect may be deficient in some neuroblastoma tumours, and is vital to the anticancer effect of vitamin A in neuroblastoma cells. In this application we hope to define those cellular factors which are necessary for turning on the expression of this gene.Read moreRead less
Improving The Efficacy Of Retinoid Therapy In Childhood Neuroblastoma
Funder
National Health and Medical Research Council
Funding Amount
$295,336.00
Summary
Cancer is still the commonest disease causing death in chilhood. Childhood neuroblastoma is a cancer of the nerve tissue which presents usually as a widely spread malignancy, which responds poorly to conventional therapy, indicating the need for novel treatment approaches. Vitamin A derivatives, or retinoids, given in addition to conventional therapy improves the cure rate for children with advanced neuroblastoma to 50%. We have shown that one likely mechanism of retinoid resistance is a deficie ....Cancer is still the commonest disease causing death in chilhood. Childhood neuroblastoma is a cancer of the nerve tissue which presents usually as a widely spread malignancy, which responds poorly to conventional therapy, indicating the need for novel treatment approaches. Vitamin A derivatives, or retinoids, given in addition to conventional therapy improves the cure rate for children with advanced neuroblastoma to 50%. We have shown that one likely mechanism of retinoid resistance is a deficiency of retinoic acid receptor beta, which is a necessary factor in the neuroblastoma cell for converting the retinoid anti-cancer signal into an irreversible cellular change. In this project we will define why some neuroblastoma cells express low levels of this protein and test new retinoid therapies.Read moreRead less